Condition (MeSH)
Vitreous Hemorrhage
ClinicalTrials.gov lists 39 trials for Vitreous Hemorrhage or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
39 of the 39 trials are tagged with Vitreous Hemorrhage itself; the rest are tagged with a narrower condition beneath it.
When did Vitreous Hemorrhage trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 3 |
| 2020 | 2 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 2 |
| 2013 | 2 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Vitreous Hemorrhage trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 3 | 7 |
| Phase 4 | 6 |
| Not applicable | 12 |
| Observational | 5 |
How many Vitreous Hemorrhage trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 24 |
| Withdrawn | 2 |
| Unknown status | 10 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Vitreous Hemorrhage trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alcon Research | 2 |
| Bausch & Lomb Incorporated | 2 |
| National Eye Institute (NEI) | 2 |
Which drugs are being tested for Vitreous Hemorrhage? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| rHuPH20 | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Bevacizumab 1 | 10 |
| SHAM injection | 2 |
| ranibizumab PRN | 2 |
| Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml) | 1 |
| 1% Sevoflurane | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Vitreous Hemorrhage trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Congestive heart failure | 8 | 1 |
| Kidney failure | 8 | 1 |
| Pneumonia | 8 | 2 |
| Foot infection | 7 | 1 |
| Retinal detachment | 7 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Vitreous Hemorrhage? (44)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. | JAMA | 2020 | Yes |
| FIRST-IN-HUMAN CLINICAL STUDY TO INVESTIGATE THE EFFECTIVENESS AND SAFETY OF PARS PLANA VITRECTOMY SURGERY USING A NEW HYPERSONIC TECHNOLOGY. | Retina (Philadelphia, Pa.) | 2020 | Yes |
| Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial. | BMC ophthalmology | 2020 | Yes |
| Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial. | The British journal of ophthalmology | 2019 | Yes |
| VISUALIZATION FROM INTRAOPERATIVE SWEPT-SOURCE MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY IN VITRECTOMY FOR COMPLICATIONS OF PROLIFERATIVE DIABETIC RETINOPATHY. | Retina (Philadelphia, Pa.) | 2018 | Yes |
Showing 5 of 44 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.